STOCK TITAN
  1. Home
  2. News
  3. VBIV

VBI Vaccines Inc. - VBIV STOCK NEWS

Welcome to our dedicated news page for VBI Vaccines (Ticker: VBIV), a resource for investors and traders seeking the latest updates and insights on VBI Vaccines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VBI Vaccines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VBI Vaccines's position in the market.

News
VBI Vaccines Reports Full Year 2023 Financial Results
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) reports a 234% increase in global net revenue for PreHevbrio® (Hepatitis B Vaccine [Recombinant]) from 2022 to 2023. Preliminary 2024 U.S. sales show significant growth, with 65% of 2023 volume sold in Q1 2024. Positive early data from Phase 2b study of VBI-1901 in recurrent glioblastoma. The company focuses on financial stability, debt reduction, and operational efficiency to drive sustainable growth and value for stakeholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
earnings
-
News
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) closes a registered direct offering, raising approximately $2 million. The offering included 2,272,728 common shares and warrants at $0.88 per share. The net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
offering
-
News
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) announces a registered direct offering of 2,272,728 common shares at $0.88 per share and unregistered warrants to purchase up to 2,272,728 common shares with an exercise price of $0.76 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.34%
Tags
offering
News
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
Rhea-AI Summary
VBI Vaccines Inc. presents promising early tumor response data from Phase 2b study of VBI-1901 in recurrent glioblastoma at World Vaccine Congress 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
-
News
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Rhea-AI Summary
VBI Vaccines expands collaboration with the Canadian government to accelerate development of its novel MLE technology platform. The partnership will direct CAD$28 million towards VBI's proprietary technology platforms, including the MLE platform, showing promising preclinical results and potential for streamlined manufacturing timelines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.9%
Tags
partnership
-
News
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
Rhea-AI Summary
VBI Vaccines Inc. (VBIV) announced agreements with Brii Biosciences for up to $33 million in consideration, involving the acquisition of intellectual property, manufacturing capabilities, and exclusive licensing for immunotherapeutic candidates. The deal aims to reduce VBI's debt and enhance financial stability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
none
News
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Rhea-AI Summary
Brii Biosciences Limited acquires all intellectual properties related to BRII-179, eliminates future milestone and royalty payments to VBI, and secures rights to VBI-1901 APAC, expanding global commercial supplies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.12%
Tags
acquisition
-
News
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV) announced additional biomarker data from the Phase 1/2a study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients. The data showed T-cell activation capable of trafficking across the blood-brain barrier to the tumor microenvironment, with higher levels of C4G associated with longer progression-free survival. The Phase 1/2a study in recurrent GBM patients demonstrated a 44% disease control rate, with 2 partial tumor responses observed. The ongoing Phase 2b study aims to further evaluate VBI-1901's safety and efficacy in up to 60 patients with first recurrent GBM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.29%
Tags
clinical trial
-
News
VBI Vaccines Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
VBI Vaccines Inc. (Nasdaq: VBIV): Global net revenue for PreHevbrio, the Hepatitis B Vaccine [Recombinant], surged 52% quarter-over-quarter from Q2 to Q3 2023. The company reported continued execution across its earlier-stage pipeline, including the initiation of a Phase 2b study for VBI-1901 in recurrent glioblastoma patients, interim Phase 1 data for pan-coronavirus candidate VBI-2901, and the announcement of novel mRNA-launched eVLP platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
earnings
News
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
Rhea-AI Summary
VBI Vaccines Inc. has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology. Preclinical studies have shown that the new technology generates stronger B- and T-cell signals compared to other mRNA vaccines. The technology also offers streamlined manufacturing processes and timelines. VBI's MLE technology has the potential to produce highly potent vaccines in an accelerated timeframe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
none
Stock VBIV logo
VBI Vaccines Inc.

Nasdaq:VBIV

VBIV Rankings

#5172 Ranked by Market Cap
#5527 Ranked by Stock Gains
N/A Ranked by Dividends

VBIV Stock Data

16.42M
20.44M
7.69%
11.84%
1.22%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Cambridge

About VBIV

vbi vaccines inc. (nasdaq: vbiv) is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. vbi’s evlp vaccine platform allows for the design of enveloped (“e”) virus-like particle (“vlp”) vaccines that closely mimic the target virus. the company’s lead evlp asset is a prophylactic cytomegalovirus (cmv) vaccine; vbi has initiated work for gmp manufacturing of its cmv candidate for use in formal preclinical and phase i trials. the company’s second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. vbi has completed proof of concept thermostability studies on a number of vaccine and biologic targets. vbi is headquartered in cambridge, ma with research facilities in ottawa, canada.